Search results
Results from the WOW.Com Content Network
Novartis also initiated a program to assist patients who could not afford its version of the drug, concurrent with its product launch. [177] When examination of Novartis' patent application began in 2005, it came under immediate attack from oppositions initiated by generic companies that were already selling Gleevec in India and by advocacy ...
Novartis v. Union of India & Others is a landmark decision by a two-judge bench of the Indian Supreme Court on the issue of whether Novartis could patent Gleevec in India, and was the culmination of a seven-year-long litigation fought by Novartis. The Supreme Court upheld the Indian patent office's rejection of the patent application.
In 2017, the ABX patent was also acquired by Endocyte [16] and Endocyte together with the above two sets of patents was acquired by Novartis in 2018. [17] Efficacy and safety was initially investigated as a compassionate access treatment in Germany with high tumor targeting and low doses to normal organs. [18]
In April 2016, Novartis announced that bimagrumab had failed a Phase IIb/III study for sporadic inclusion body myositis. [6] In January 2021, a new study confirmed that treatment with Bimagrumab is safe and effective for treating excess adiposity and metabolic disturbances of adult patients with obesity and type 2 diabetes. [ 7 ]
Novartis had filed a patent for Glivec in 1997. [30] An exclusive marketing right was also granted for Novartis in 2003 and the application were approved in 2005 . [ 30 ] In 2013, the Supreme Court of India upheld the rejection of the patent application of Glivec by Novartis , [ 31 ] ending the 10-years battle between the proprietary drug ...
[5] [6] The company's CEO resigned six weeks later, and patent rights to the PCR process were sold to Hoffman-La Roche. Losses continued, and in 1991 the company was sold to Chiron Corporation. [7] Chiron continued the development of IL-2, which was finally approved by the FDA in 1992.
Advanced Accelerator Applications (AAA or Adacap) is a France-based pharmaceutical group, specialized in the field of nuclear medicine. [1] The group operates in all three segments of nuclear medicine (PET, SPECT and therapy) to diagnose and treat serious conditions in the fields of oncology, neurology, cardiology, infectious and inflammatory diseases.
Coincidentally, Tanox started to receive major patents for its anti-IgE invention from the European Union and from the U.S. in 1995. [58] After a 3-year legal entanglement, Genentech and Tanox settled their lawsuits out-of-court and Tanox, Novartis, and Genentech formed a tripartite partnership to jointly develop the anti-IgE program in 1996. [59]